← Alle mensen

TM

Tae Min Kim

12 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Blood · 15 januari 2026
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, r...
Lancet (London, England) · 10 januari 2026
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Gevorderd NSCLC.
The New England journal of medicine · 1 januari 2026
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to Eerstelijns Pembro...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-02
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Ther...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-02
Atezolizumab plus bevacizumab plus chemo bij EGFR-gemuteerd NSCLC: IMpower150 subgroep
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024
Canakinumab plus pembrolizumab-chemo bij gevorderd NSCLC: CANOPY-1 fase III
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 januari 2024
Pola-R-CHP bij onbehandeld DLBCL: Aziatische POLARIX subanalyse
Blood · 20 april 2023
Bintrafusp alfa (bifunctioneel anti-TGFβ/PD-L1) als tweedelijns bij NSCLC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020-07
Polatuzumab vedotin bij recidief/refractair DLBCL: fase Ib/II
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 januari 2020
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab bij melanoom: ECHO-301/KEYNOTE-252
The Lancet. Oncology · 2019-08
Ceritinib versus chemotherapie bij ALK-positief NSCLC na eerdere chemotherapie en crizotinib: ASCEND-5
The Lancet. Oncology · 2017-07